AML1/RUNX1 mutations have been reported frequently in myelodysplastic syndrome (MDS) patients, especially those diagnosed with refractory anemia with excess blast (RAEB), RAEB in transformation (RAEBt), or AML following MDS (these categories are defined as MDS/AML). Although AML1 mutations are suspected to play a pivotal role in the development of MDS/ AML, acquisition of additional genetic alterations is also necessary. We analyzed gene alterations in MDS/AML patients with AML1 mutations, comparing them to alterations in those without an AML1 mutation. AML1 mutations were significantly associated with À7/7q-, whereas MDS/AML patients without AML1 mutations showed a high frequency of À5/5q-and a complex karyotype. Patients with AML1 mutations showed more mutations of their FLT3, N-RAS, PTPN11, and NF1 genes, resulting in a significantly higher mutation frequency for receptor tyrosine kinase (RTK)-RAS signaling pathways in AML1-mutated MDS/AML patients compared to AML1-wild-type MDS/AML patients (38% versus 6.3%, Po0.0001). Conversely, p53 mutations were detected only in patients without AML1 mutations. Furthermore, blast cells of the AML1-mutated patients expressing surface c-KIT, and SHP-2 mutants contributed to prolonged and enhanced extracellular signalregulated kinase activation following stem cell factor stimulation. Our results suggest that MDS/AML arising from AML1/ RUNX1 mutations has a significant association with À7/7q-alteration, and frequently involves RTK-RAS signaling pathway activation.
Introduction
Somatically acquired point mutations of critical genes have been demonstrated to contribute to the development of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Genes encoding key regulatory factors for cell division, differentiation, or cell survival of hematopoietic progenitors, as well as transcription factors, are frequent mutation targets. The AML1/RUNX1 gene was also found to be altered by point mutations in AML and MDS, and unique features associated with these mutations have been revealed by several studies.
First, although the frequency of AML1 mutations in de novo AML is low, they have been detected with a substantially higher frequency in poorly differentiated AML M0, [1] [2] [3] and in radiationassociated and therapy-related AML. 4, 5 Second, germ-line mutations of AML1 have been shown to occur in a rare autosomal dominant disorder, familial platelet disorder with predisposition to AML (FPD/AML). 6, 7 Third, we previously reported a high frequency of AML1 mutations in MDS patients, especially those with refractory anemia with excess blast (RAEB), RAEB in transformation (RAEBt), and AML following MDS (these categories are defined as MDS/AML). 8 This suggests that AML1 point mutations are strongly associated with these specific types of hematopoietic malignancy. In the molecular pathogenesis, de novo AML is often associated with oncogenic chimeras such as AML1-ETO (MTG8), which are considered to be the major cause of malignant transformation of hematopoietic progenitors, while point mutations are likely a complement for chimeras. However, AML1 point mutations should be considered one of the major decisive factors of the development of MDS/AML, similar to chimeras in de novo AML.
All of the AML1 mutants detected so far, with a few exceptions, showed a lowering or loss of their trans-activation potential, regardless of their DNA-binding potential. This suggests that various AML1 mutants act through a loss-offunction mechanism, and contribute to development of the same type of myeloid malignancy, MDS/AML. However, loss of AML1 function caused by AML1 mutations in hematopoietic stem cells is not sufficient for an individual to develop MDS/ AML, and this explains the long latency period before development of AML among people having FPD/AML pedigrees with congenital AML1 mutations. Moreover, AML1
þ /À mice, conditional AML1 À/À mice or conditional heterozygous AML1-ETO knockin mice do not develop leukemia without mutagenic reagents, in spite of the increase in number and the self-renewal capacity of their hematopoietic stem cells. 9, 10 This in turn suggests that the acquisition of some additional genetic alterations that cooperate with the AML1 mutations is needed for development of MDS/AML. Recently, c-kit activating mutations were identified in 20-30% of CBF leukemia patients who had blasts containing either AML1-ETO or CBFb-MYH11 fusion proteins. 11 This was not observed in any of the non-CBF leukemias, suggesting that the expression of CBF fusion proteins provides a selective advantage for acquisition of a c-kit mutation, and that these events function together in the development of leukemia. This theory supports a 'two-hit' model for leukemogenesis. 12 The basis for the hypothesis is that AML is the consequence of a collaboration between at least two broad classes of mutation: class I (proliferative) mutations that confer a proliferative and/or survival advantage to cells, including gene alterations of RAS, c-KIT, FLT3, PTPN11 and NF1, and class II (blocking) mutations that primarily impair hematopoietic differentiation and subsequent cellular apoptosis, including AML1-ETO and CBFb-MYH11 fusion genes. AML1 point mutations are classified as class II mutations, and FLT3 mutations were frequently observed in AML1-mutated AML M0 patients. 13 It is hard to explain the molecular mechanisms in MDS that contribute to the transformation of hematopoietic progenitors by a simple 'two-hit' model. Many cases of MDS are generally considered to develop as a result of accumulated gene deletions and point mutations. Genetic alterations associated with MDS have been identified, including receptors for hematopoietic growth factors, RAS signaling molecules, cell cycle regulators and transcriptional factors. 14, 15 However, these are all relatively rare (o10%) and none are specific to MDS. Chromosomal abnormalities are also associated with MDS, and they vary from single numerical or structural changes to complex genomic lesions. 14, 15 Unbalanced numeric chromosomal alterations, including partial and complete chromosome loss (especially 5q-, À7, ÀY and 20q-) or chromosome gain (most frequently þ 8), predominate in MDS. A model of stepwise genetic progression has emerged, based on genetic and cytogenetic findings, to explain the development and evolution of MDS. 16 In this model, a primary genetic event incites the initial DNA damage and subsequently increases the susceptibility to further damage. Secondary genetic events promote acquisition of molecular-genetic or cytogenetic abnormalities common to MDS and precipitate additional abnormalities.
Myelodysplastic syndrome is a quite heterogeneous disease category. We have been trying to re-classify MDS based on the molecular pathogenesis, and have proposed a new disease entity, MDS/AML with AML1 point mutations. In this subgroup of MDS, an AML1 mutation is considered to be the primary genetic event. Similar to CBF leukemia, patients with MDS/AML with AML1 mutations probably also have some selective secondary genetic events. Here, we report a high frequency of mutations affecting the class III receptor tyrosine kinase (RTK)-RAS signaling pathway in AML1-mutated MDS/AML patients. Our data suggest that AML1 point mutations affect activation of the RTK-RAS signaling pathway, and that this may be one of the molecular mechanisms to develop MDS/AML.
Materials and methods

Patients
We examined 625 patients with hematologic diseases, including MDS, AML, acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML) and myeloproliferative disorder (MPD), all of whom were diagnosed at Hiroshima University Hospital and its affiliated hospitals between 1990 and 2004. Diagnosis was based on morphologic and immunophenotypic studies according to the French-American-British (FAB) classification. Three disease categories corresponding to subgroups of MDS and AML were identified (i.e., RAEB, RAEBt and AML following MDS) as MDS/AML. 8 Cytogenetic analyses using standard procedures were performed according to the International System of Human Cytogenetic Nomenclature (1995) . 17 The majority of the patients in this study were treated at Hiroshima University Hospital or Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital using a protocol involving intensive chemotherapy and bone marrow transplantation.
Patient samples were taken after obtaining informed consent and approval from the institutional review board at Hiroshima University. Mononuclear cells were isolated from bone marrow or peripheral blood samples by Ficoll-Conray density gradient centrifugation. Genomic DNA was extracted with a Puregene Kit (Gentra, Minneapolis, MN, USA) and total RNA was extracted using a TRIzol Kit (Invitrogen, Carlsbad, CA, USA), according to the manufacturers' instructions.
Identification of AML1 mutations
Mutation analysis of AML1 exons 3-8 was performed by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) of all 625 patients as described previously. 8 Briefly, 100 ng of genomic DNA was amplified by PCR using the flanking intronic, forward/reverse primers (Supplementary Table) . To identify AML1 mutations, SSCP analysis was performed on a GenePhor system (Amersham Pharmacia Biotech, Buckinghamshire, UK). PCR products that showed abnormal bands were sequenced in both directions. To confirm the mutations, PCR products from cDNA were also sequenced.
We selected patients for further studies according to their diagnosis and their AML1 mutations, and they were divided into three disease categories as follows: (1) 
Denaturing high performance liquid chromatography analysis
PCR-amplified samples were warmed to 951C, then cooled to 251C over approximately 45 min to promote heteroduplex formation. Denaturing high performance liquid chromatography (DHPLC) was performed on a WAVE DNA fragment analysis system (Transgenomic, Omaha, NE, USA). Briefly, 5 ml of each DNA sample was injected into a high-throughput DNASep column and eluted through a 260 nM photodetector with concentrations of buffer A and B (Transgenomic) adjusted automatically as calculated by the Navigator software package (Transgenomic). All samples were run at the oven temperature listed in the Supplementary Table. The Navigator software predicted that each segment of the exonic component of the amplicon would be under partially denaturing conditions at these temperatures. For each abnormal elution profile, genomic DNA was re-amplified and the PCR products were directly sequenced.
Direct sequencing
The PCR-amplified product was electrophoresed through a 2% agarose gel. The bands of interest were excised from the agarose gel and purified using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). Purified DNA fragments were sequenced in both directions using a BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) and were analyzed on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). To confirm the mutations, a second independent PCR amplification and subsequent bidirectional sequencing were performed.
Screening for the internal tandem duplication and the D835 mutation of the FLT3 gene
The FLT3 internal tandem duplication (ITD) was examined by amplification of the juxtamembrane (JM) domain using forward/ reverse primers (Supplementary Table) , followed by electrophoresis in an agarose gel, as reported previously. 23 Additional bands, indicative of ITD, were cut out for direct sequencing. Screening for the D835 mutation was carried out by amplification of genomic DNA using forward/reverse primers (Supplementary Table) . PCR products were digested with EcoRV and were then resolved on an agarose gel, as described previously. 24 Direct sequencing was carried out on samples with an undigested band.
Plasmid constructions
PCR-generated fragments of PTPN11 cDNA encoding SHP-2 or SHP-2 mutants with the C-terminus c-myc epitope tag were subcloned into the pcDNA3.1 expression vector (Invitrogen). The wild-type PTPN11 cDNA was mutated at nucleotides 181 (G4T) or 226 (G4A) using PCR-based mutagenesis to yield amino-acid changes D61Y or E76K, respectively. The integrity of the amplified sequence was confirmed by DNA sequencing.
Cell culture and transfection
HEL cells were maintained in RPMI1640 (Invitrogen) with 10% fetal calf serum (FCS), 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin and grown at 371C in a humidified atmosphere with 5% CO 2 . The plasmids were transfected into HEL cells by electroporation (300 V, 1050 mF) using a Gene Pulser (Bio-Rad, Hercules, CA, USA). Transfected cells were selected with 1 mg/ml G418 (Invitrogen), cloned by limiting dilution, and analyzed for SHP-2 expression by Western blot. Cells were washed with RPMI1640 containing 10% FCS three times, resuspended in the same medium alone or supplemented with 100 ng/ml of stem cell factor (SCF) (PeproTech, Rocky Hill, NJ, USA).
Immunoblotting
For immunoblot analysis, cells were solubilized in NP-40 lysis buffer (50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1% NP-40) containing a protease inhibitor mixture (Complete; Roche). In order to detect phosphorylation, a phosphatase inhibitor mixture (50 mM sodium fluoride, 10 mM sodium pyrophosphate, 2 mM sodium orthovanadate) was added to the lysis buffer. Protein concentrations were determined with Bradford reagents (BioRad). For Western blot, the lysates were boiled in Laemmli buffer and then separated by 15% SDS-PAGE gel and transferred to Hybond enhanced chemiluminescence (ECL) (Amersham Pharmacia Biotech). The membrane was blocked in 5% non-fat milk in PBS containing 0.1% Tween-20 and incubated sequentially with primary antibodies and a horseradish peroxidase-conjugated secondary antibody (Amersham Pharmacia Biotech). The primary antibodies used in this study were anti-Myc antibody, anti-c-kit polyclonal antibody, anti-SHP-2 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p44/42 MAP kinase polyclonal antibody and anti-phospho-p44/42 MAP kinase polyclonal antibody (Cell Signaling Technology, Beverly, MA, USA). Bound antibodies were detected by ECL using a Western blotting kit (Amersham Pharmacia Biotech).
Results
The difference of cytogenetic findings in MDS/AML patients with or without an AML1 point mutation
We previously reported 32 cases of hematological disease associated with somatic mutations of the AML1 gene. 8 We then extended the mutation analysis by PCR-SSCP assay using genomic DNA, and thereby found 13 new cases. The clinical findings of 10 patients with MDS/AML are summarized in Table 1 (cases 33 -42) . Two patients with secondary AML had frame shift and nonsense mutations, and one patient with reactive leukocytosis had the same silent mutation we previously reported in an MDS RA patient (case 1). 8 We selected the patients according to their diagnosis and AML1 mutations, and divided them into three disease categories: (A) MDS/AML patients with an AML1 mutation; (B) MDS/AML patients without an AML1 mutation; and (C) CBF leukemia patients (8;21 translocation and inversion 16). Two patients (cases 2 and 15) who had silent mutations were excluded from the group of patients with AML1 mutations because these mutations represent a simple polymorphism, and indeed we found one silent mutation in a reactive leukocytosis patient as well. We analyzed 34 MDS/AML patients with AML1 mutations summarized in Table 1 , including the previously published 24 cases designated as nos. 3-9 and 16-32, 8 80 MDS/AML patients without an AML1 mutation and 25 CBF leukemia patients. This analysis included 28 cases of secondary MDS/AML: 13 with AML1 mutations (six atomic-bomb survivors, five patients who received previous chemotherapy and/or radiotherapy, one atomic-bomb survivor who also received previous chemotherapy and one case of exposure to mustard gas), and 15 patients without AML1 mutations (seven atomic-bomb survivors and eight therapyrelated patients).
The cytogenetic findings of AML1-mutated patients were compared with those of AML1-wild-type patients to see whether the AML1-mutated patients had distinct cytogenetic characteristics (Table 2) . Five previously reported patients who showed a normal karyotype (cases 9, 19, 25, 26 and 29) had minor but clonal karyotypic abnormalities; case 9: 47, XX, þ 1, der(1;7) (q10;p10), i(21)(q10), case 19: 47, XY, del(7)(q22q32), þ 8, case 25: 47, XY, dup(1)(q21q44), þ 8, case 26: 45, XY, À7 and case 29: 44, XX, À7, À17. Clonal cytogenetic abnormalities could be detected in more than half of the patients with MDS/ AML, 19 (56%) of the 34 patients with AML1 mutations and 47 (59%) of the 80 patients without AML1 mutations. A complex karyotype (five or more aberrations) was seen in 20 (25%) of the 80 patients without an AML1 mutation, whereas it was not seen in the patients with an AML1 mutation (P ¼ 0.0007).
Most chromosomal aberrations were unbalanced numeric alterations, including partial and complete chromosome loss or chromosome gain, in both groups of patients. À5/5q-was found with a significantly higher frequency in the AML1-wild-type group compared with the AML1-mutated group (17/80 versus 0/34, P ¼ 0.0027), but no significant association was observed between AML1 mutations and À7/7q-, 20q-or þ 8. However, half of the patients with a complex karyotype had more than 10 aberrations, and many of them had both À5/5q-and À7/7q-abnormalities. Therefore, we compared the incidence of À7/7q-with a normal chromosome 5 between AML1-mutated patients and AML1-wild-type patients (Table 2 ). This 'simple' À7/7q-abnormality was seen in nine (26%) of the 34 patients with AML1 mutations, and in three (4%) of the 80 patients without AML1 mutations (P ¼ 0.0009). Of the four patients with AML1-mutated MDS/AML (cases 8, 9, 22 and 42) who had a history of treatment with alkylating agents, three patients presented the À7/7q-cytogenetic abnormalities.
À7/7q-and N-RAS mutation are closely related to AML1 mutations in patients developing MDS after chemotherapy for AML We identified two patients who developed MDS/AML with AML1 mutations after receiving chemotherapy for AML (Figure 1) . At the point of AML diagnosis, they did not show AML1 mutations. Several years after they achieved complete remission, they developed MDS with AML1 mutations. Interestingly, the À7/7q-chromosomal abnormality and the N-RAS mutation also developed at the time of MDS diagnosis. One patient (case 8) had a history of receiving chemotherapy, including alkylating agents and all-trans retinoic acid, for AML (M3). This patient had a normal karyotype and a PML-RARa oncogenic chimeric gene. Continuous complete remission (CCR) was achieved for 3 years, and then she developed MDS (RAEBt). No mutation was found in either the AML1 or the N-RAS gene before she developed MDS. At the time of MDS diagnosis, she had a karyotypic abnormality of monosomy 7. Moreover, she gained not only an AML1 mutation but also an 
Genetic abnormalities in MDS/AML patients with AML1 point mutation
To investigate the gene mutations in patients with MDS/AML or CBF leukemia, we analyzed the N-RAS, K-RAS, PTPN11, NF1, FLT3, c-KIT and p53 genes (Table 3) . We found a total of nine N-RAS mutations, four PTPN11 mutations, two NF1 mutations, eight FLT3 mutations, six c-KIT mutations and 12 p53 mutations. Two patients with an AML1 mutation had two additional mutations (N-RAS and PTPN11, PTPN11 and FLT3). No mutation of the K-RAS gene was detected in these patients with MDS/AML or CBF leukemia. Activating RAS mutations, loss-offunction mutations in NF1 and gain-of-function PTPN11 mutations imply that there is upregulation of the RAS signaling pathway. Furthermore, activating mutations of c-KIT and FLT3 also induce activation of the RAS signaling pathway. N-RAS, PTPN11, NF1 and FLT3 mutations were more frequent in AML1-mutated MDS/AML patients compared with AML1-wild-type MDS/AML patients (15 versus 3.8%, 12 versus 0%, 6.5 versus 0%, and 12 versus 2.5%, respectively), but not significant except for PTPN11 (P ¼ 0.0069). However, the frequency of all these mutations affecting the RTK-RAS signaling pathway was significantly higher in AML1-mutated MDS/AML patients than in AML1-wild-type MDS/AML patients (38 versus 6.3%, Po0.0001). Conversely, p53 mutations were not detected in the 34 patients with AML1 mutations, but were detected in 12 (15%) of the 80 patients without AML1 mutations (P ¼ 0.0170).
Mutations in c-KIT were frequently detected in CBF leukemia patients, but were not detected in any of the patients with MDS/ AML. Furthermore, similar to MDS/AML patients with AML1 point mutations, a high frequency (nine of 25, 36%) of RTK-RAS signaling pathway mutations was observed in patients with CBF leukemia.
SHP-2 mutants contribute to prolonged and enhanced extracellular signal-regulated kinase activation following stem cell factor stimulation Somatic mutations in PTPN11 are known to upregulate SHP-2 physiologic activation, leading to RAS pathway activation. This gain of function in mutated SHP-2 depends on ligand stimulation. Epidermal growth factor (EGF), 25, 26 and granulocytemacrophage colony stimulating factor (GM-CSF) 27 are known as ligands that upregulate mutated SHP-2, but so far SCF has not been known as such as a ligand. In AML1-mutated MDS/AML patients, genes involved in the RTK-RAS signaling pathway were frequently mutated, and blast cells of these patients expressed surface c-KIT (data not shown). Therefore, we suspected that cells bearing SHP-2 mutants would send strong stimulation signals through the RTKs, especially c-KIT. To investigate the effect of the mutant SHP-2 molecules on the RTK-RAS signaling pathway activation in response to SCF, we used HEL cells, which express the SCF receptor protein c-KIT. We established cell lines stably expressing Myc-tagged wildtype or mutant SHP-2 proteins (Figure 2 ). D61Y and E76K mutant SHP-2 proteins were previously identified in samples from patients with juvenile myelomonocytic leukemia (JMML), and their molecular characteristics have been thoroughly analyzed. 25, 27, 28 Cells were stimulated with SCF for various amounts of time, and we examined the activation of a downstream effector of RAS, extracellular signal-regulated kinase (ERK). Levels of phospho-ERK (p-ERK) at baseline were not elevated in cultures transduced with any SHP-2 constructs compared with parental HEL cells (compare lane 1 with lane 8 in Figure 2b ). The HEL cells expressing wild-type SHP-2 showed activation of ERK at 5 min after SCF stimulation, a maximum activation level at 10 min, and p-ERK levels returned to baseline after 30 min. In cells expressing mutant SHP-2, SCF stimulation induced a prolonged and more intense signal of p-ERK lasting up to 60 min (Figure 2b, c) . Although previous reports showed that the D61Y mutant was less hypersensitive than E76K in response to GM-CSF and IL-3, 27,28 our data showed that hyperactivity to SCF stimulation was detected slightly more in the D61Y-expressing cells than in the E76K-expressing cells (Figure 2b , c). The discrepancies between these studies and our data might be due to differences in the cytokine-dependent or independent cell systems and/or stimulating cytokines. The mechanism of different reactivities between these mutants is unclear, but may be caused by a minute structural difference.
Discussion
In this study, we have demonstrated correlations between AML1 point mutations and À7/7q-or gene mutations affecting the RAS signaling pathway in patients with MDS/AML (i.e., RAEB, RAEBt and AML following MDS). This correlation was also shown in the clinical course of two patients who developed therapyrelated MDS/AML with a combination of an AML1 mutation, a À7/7q-abnormality and an N-RAS mutation induced by chemotherapy for AML (Figure 1) .
Our study revealed a significant association between AML1 mutations and À7/7q-, and between normal AML1 and À5/5q-in both sporadic and secondary cases of MDS/AML patients. Previous studies have shown that the genetic pathways for development of MDS/AML may be classified by the cytogenetic Patients including one case with +21, one case with +21q and three cases with balanced translocations with the break point of 21q22.
Hyperactivation of RAS pathway in AML1-mutated MDS H Niimi et al RTK ¼ receptor tyrosine kinase. *Fisher's exact probability test was used to determine the P-value. N-RAS mutations were G12V, G13D, G60E, Q61K and Q61H; PTPN11 mutations were N58Y, F71L and A72T; NF1 mutations were C118fsX164 and S382fsX390; FLT3 mutations were tandem duplications ranged in size from 7 to 24 amino acids and D835Y; c-KIT mutations were TYD417_419FG, D816A, D816Y and D816V; and p53 mutations were Y126C, S127C, V143M, R175H, H179Y, H214R, Y234C, R248Q, Y236X and C275F.
abnormalities or by the patient's previous exposure to chemotherapy. Two main cytogenetic pathways have been proposed to explain the malignant transformation step in patients with therapy-related MDS (t-MDS): [29] [30] [31] pathway I is 'À7/7q-with normal chromosome 5', and pathway II is 'À5/5q-'. The patients belonging to the pathway I group frequently show mutations of RAS genes 32 and methylation of the p15 INK4b gene promoter. 33 A more recent study has shown that AML1 mutations in patients with t-MDS were highly significantly associated with À7/7q-. 5 On the other hand, patients belonging to pathway II frequently present a complex karyotype and a mutation of p53, whereas pathway I has a very low frequency of p53 mutations. 22, 34 However, we have focused on the pivotal role of AML1 mutations, rather than cytogenetic abnormalities, during the development of MDS/AML. We are trying to define the disease entity of 'MDS/AML with AML1 mutation', which could be considered for inclusion in the recurrent genetic abnormalities under the WHO classification. Thus, we have attempted to classify the genetic pathway of developing MDS/ AML with or without AML1 mutations.
Many reports have shown that genes involved in the RAS signaling pathway are mutated in hematopoietic diseases. In MDS, mutations of the N-RAS gene have been known to be a frequent (B10%) genetic alteration, 35 and these typically occur during transformation to AML. However, mutations of PTPN11 have been reported to be rare in adult MDS (2 of 189 MDS/AML, 1.1%), [36] [37] [38] although they have been frequently found in childhood MDS. 25 Mutations of the NF1 gene are also very rare in adult MDS. 39 Mutations of the FLT3 gene are found in 5% of MDS patients, and are associated with leukemic transformation. 40, 41 In this study, we found a significantly higher mutation frequency of these genes in MDS/AML patients with AML1 mutations than in those without an AML1 mutation (38 versus 6.3%, Po0.0001). The high frequency of these mutations in patients with AML1 mutations leads us to consider that mutations in the RAS pathway, besides being valuable deciding factors for prognosis, may function also as genetic partners of the AML1 mutations. Mutations of RAS, NF1 or PTPN11 are seen in most patients with JMML, a MPD of young children. 28 All mouse models bearing a heterozygous Nf1 (Nf1 þ /-), 42 a conditional inactivation of Nf1 (Nf1 -/-), 43 a conditional expression of activating K-ras mutation (K-ras G12D/ þ ), 44, 45 or a heterozygous Ptpn11 mutation (Ptpn11 D61G/ þ ) 46 developed a myeloproliferative disease. Thus, we suggest that these gene alterations might work as 'proliferative' partners of the AML1 mutations. Which ligand/receptor system would be involved in stimulation of this pathway? Most previous studies of gene mutations affecting the RAS pathway have revealed the hypersensitive proliferation of hematopoietic progenitor cells by using a stimulating ligand of GM-CSF, especially in the studies of JMML. 44, 46, 47 However, GM-CSF seems not to be essential for proliferation of hematopoietic stem cells expressing CD34 in patients with MDS. CD34-positive hematopoietic stem cells express the c-KIT receptor protein, and AML1 is required for the generation of these cells. 48 Moreover, c-KIT mutations and/or overexpression are frequently seen in patients with CBF leukemia in which AML1 functions are impaired ( Table 3) . 11, 49, 50 These gain-of-function mutations of c-KIT result not only in constitutive activation but also in receptor hyperactivation in response to SCF stimulation. 51 In the patients with AML1-mutated MDS/AML, a disease characterized by impaired AML1 function that is similar to CBF leukemia, we did not find any c-KIT mutation. However, blast cells of these patients expressed c-KIT, and SCF stimulation of c-KIT expressing HEL cells bearing SHP-2 mutants yielded hyperactivation of the RAS pathway (Figure 2 ). Taken together, these results suggest that SCF stimulation via the c-KIT receptor might be important for activating the RAS pathway in AML1-mutated MDS/AML patients, and hyperactivation of the RTK-(especially c-KIT-) RAS pathway may be a common genetic event in hematological malignancies with impaired AML1. In further support of this hypothesis, the AML1-ETO chimeric protein represses NF1 expression. 52 The somatic mutations associated with some additional factors in the RTK-RAS pathway still remain unknown. Genes encoding these factors also might be altered in hematological diseases characterized by AML1 impairment. To clarify the cooperative functions of AML1 mutations and hyperactivation of the RAS pathway in development of MDS/ AML, mice carrying both gene mutations are currently being established in our laboratory, and we will address these questions in future studies.
Here, we propose two genetic pathways in the development of MDS/AML (Figure 3 ). One is a pathway 'with AML1 mutation'. In this pathway, AML1 mutations, similar to chimeras in de novo AML, would be considered to be the major decision factor to develop MDS/AML and would inhibit the differentiation of hematopoietic stem cells. A hematopoietic stem cell that has acquired AML1 gene mutation apparently requires a long latency period to be transformed and to be conferred a proliferative and/or survival advantage by gene alterations belonging to the RTK-RAS signal transduction pathways, leading to development of MDS/AML. During this process, loss of the long arm of chromosome 7, the critical region at 7q22.1 possibly related to DNA repair genes, 53 would also play an important role in this pathway. It is suspected that some more patients with MDS/AML who have an AML1 haploinsufficiency so far undetected (such as micro-deletion of 21q22, methylation of the promoter, etc.) still exist, and they should be included in this pathway. The other pathway is one without an AML1 mutation. In this pathway, the master genetic events that inhibit the differentiation of hematopoietic stem cells are still unknown. However, patients without AML1 mutation frequently show the 5q-chromosomal abnormality. A recent paper showed that mice carrying heterozygous Nucleophosmin 1 gene, which maps to 5q35 in human, developed a hematological syndrome with features of human MDS. 54 Haploinsufficiency of nucleophosmin might be one of the master genetic events of the pathogenesis of MDS/AML in this pathway. Furthermore, p53 gene alterations are considered to work as a genetic partner leading to development of MDS/AML in this pathway. Identification of a relevant genetic pathway in MDS/AML pathogenesis may lead us to develop new therapies based on a clearer understanding of disease biology.
